Who We Are
The CTSR technology was invented by Simurx scientist, leveraging decades of experience in translationalclinical research and application. Simurx’s multidisciplinary integrative approach to product development is keenly focused on implementing innovative solutions to cancer therapy. Simurx’s CTSRplatform is a first of its kind technology that exploits the immunosuppressive nature of the tumor microenvironment to boost cell therapy efficiency and is protected by a broad patent filing.
We are motivated by a dedication to scientific rigor and the determination to improve cancer patient outcomes. Led by a skilled, innovative leadership team, supported by a multidisciplinary advisor team, and powered by committed scientists, Simurx is well positioned to bring a broad array of CAR treatments to cancer patients.
Our Platform
Our patented chimeric TGFβ-signaling receptor (CTSR) platform promotes survival in a hostile tumor environment and can be modularly combined with other engineered cell therapies
The Science
The CTSR platform soaks up immunosuppressive molecules from the tumor microenvironment while promoting proliferation and immune activation.
Our Pipeline
The modular design and inherent flexibility of our platform allow its incorporation into a multitude therapies
Latest News
Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies in Recurring Solid Tumors in Children
Regenerative medicine promises novel CAR T-cell therapies for metastatic solid tumors. LOS ANGELES (February 29, 2024)—Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches to treat children and adolescents with recurrent solid tumors. The Cancer […]
Eurekalert: Children’s Hospital Los Angeles awarded $6 million from CIRM to advance CAR T-cell therapies
Regenerative medicine promises novel CAR T-cell therapies for metastatic solid tumors. Grant and Award Announcement CHILDREN’S HOSPITAL LOS ANGELES CREDIT: CHLA LOS ANGELES (February 29, 2024)—Children’s Hospital Los Angeles has received a multi-year $6 million award from the California Institute for Regenerative Medicine (CIRM) to develop innovative stem cell approaches […]
Business Wire: Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies
Children’s Hospital Los Angeles Awarded $6 Million from CIRM to Advance CAR T-Cell Therapies in Recurring Solid Tumors in Children Business Wire Fri, Mar 1, 2024 Shahab Asgharzadeh, MD, Director, Neuroblastoma Basic and Translational Program, Division of Hematology-Oncology at The Saban Research Institute of Children’s Hospital Los Angeles and lead […]